Shared Vision for Improving Outcomes for Serious Fungal Diseases: Report of a Patient, Caregiver, and Clinician Summit
Open Access
- 26 April 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (6) , ofae226
Abstract
Background: Recently, increasing focus on patient input into research and healthcare improvements has fostered expanded patient-centered advocacy efforts. This first pan-fungal disease summit, part of the MYCology Advocacy, Research, & Education effort, brought together patients, caregivers, and mycology experts to better document patient experiences with invasive fungal disease (IFD) and establish priorities for mycology education, advocacy, and research. Methods: Patients who had suffered from IFD, their caregivers, clinicians, industry representatives, government officials, and patient advocacy professionals were invited. Patients and caregivers shared their stories and struggles with IFD. Breakout sessions separated mycology experts from patients and caregivers for further discussions to identify commonalities and perceived gaps and to formulate recommendations. The 2 groups then reconvened to develop consensus recommendations. Results: IFD patients and their caregivers shared experiences reflecting the typically lengthy prediagnosis, acute treatment, long-term treatment, and posttreatment recovery stages of IFD. They reported substantial physical, psychological, and financial burdens associated with the IFD experience, particularly related to delayed diagnoses. They reaffirmed a need for coordinated patient-centered education, peer support, and advocacy to document the burden of serious fungal infections. Mycology experts discussed strategies to address gaps in the mycology field, such as insufficient training, inadequate workforce support, and a need to partner more with patient groups. Conclusions: A summit involving patients with IFD, family caregivers, and mycology experts identified a substantial nonclinical burden of disease associated with IFD. Patients and mycology experts prioritized several goals for education, advocacy, and research to raise awareness of IFD and improve outcomes.Keywords
Funding Information
- F2G
- Astellas Pharma, USA
- IMMY
- Melinta Therapeutics
- Integrita Healthcare Education Foundation
- Centers for Disease Control and Prevention Cooperative Agreement
- University of Alabama at Birmingham (#CDC-RFA-CK20-2003)
This publication has 24 references indexed in Scilit:
- Potential missed opportunities for diagnosis of cryptococcosis and the association with mortality: A cohort studyeClinicalMedicine, 2020
- Delays in Coccidioidomycosis Diagnosis and Relationship to Healthcare Utilization, Arizona, USA 1Emerging Infectious Diseases, 2019
- Why are so many cases of invasive aspergillosis missed?Medical Mycology, 2019
- Patients’ quality of life during active cancer treatment: a qualitative studyBMC Cancer, 2018
- Antifungal resistance: current trends and future strategies to combatInfection and Drug Resistance, 2017
- The Ice Bucket Challenge: The public sector should get ready to promptly promote the sustained development of a system of medical care for and research into rare diseasesIntractable & Rare Diseases Research, 2014
- Meeting the Challenges of an Emerging Pathogen: The Henry Schueler 41&9 Foundation International Forum on MucormycosisClinical Infectious Diseases, 2012
- Recognition, Diagnosis, and Treatment of Histoplasmosis Complicating Tumor Necrosis Factor Blocker TherapyClinical Infectious Diseases, 2010
- Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patientsAmerican Journal of Health-System Pharmacy, 2009
- Advancing Outcome Measures for the New Era of Drug Development in Cystic FibrosisProceedings of the American Thoracic Society, 2007